Experts
Charles Knirsch
Vice President Clinical Affairs and ID Disease Area Lead, Pfizer
-
Developing New Vaccines Within Weeks, Not Months
Pfizer Vice President Charles Knirsch envisions a future where governments and the health industry work together to dramatically improve response times for pandemics. Read More
July 22, 2009 | In Health & Medicine, Science & Tech
-
Big Think Interview With Charles Knirsch
A conversation with Vice President Clinical Affairs and ID Disease Area Lead, Pfizer. Read More
July 22, 2009 | In Health & Medicine, Science & Tech
-
Are We Ready for Drug-Resistant Bugs?
Charles Knirsch, VP Clinical Affairs and ID Disease Area Lead at Pfizer, shares how so-called super-resistant bugs developed in New York and South Africa. Read More
July 22, 2009 | In Health & Medicine, Science & Tech
-
Globalization Begets Responsibility
To root out inequities in poverty and disease, Pfizer Vice President Charles Knirsch affirms that developed countries are obligated to stay focused on international development issues. Read More
July 22, 2009 | In Health & Medicine, Science & Tech
-
How Can Scientists Communicate Effectively Without Dumbing Down Their Message?
To regain public confidence, the pharmaceutical industry needs to convey information in simple terms, avoiding jargon, says Pfizer Vice President Charles Knirsch. Read More
July 22, 2009 | In Health & Medicine, Science & Tech
-
Fighting Global Infectious Diseases
Pfizer Vice President Charles Knirsch explains why eliminating trachoma by 2020 is a realistic goal, yet the elimination of malaria isn’t currently a viable strategy. Read More
July 22, 2009 | In Health & Medicine, Science & Tech
Charles Knirsch, MD, is Vice President and Site Head for the HIV/Anti-infectives & Clinical Support with Global Medical Research and Development, Pfizer. This group includes the triad of statistics, clinical pharmacology and the clinical therapeutic groups at the New York Development Site. Prior to this role, Chuck contributed to or led development teams that have successfully completed several sNDA’s on Pfizer’s anti-infective medicines.
Chuck completed medical school at McGill University in Montreal, Canada and a Masters in Public Health at Columbia University. He completed residency and infectious diseases training at Columbia Presbyterian Medical Center, post-doctoral fellowship training at The London School of Hygiene and Tropical Medicine and maintains an Adjunct position as Assistant Clinical Professor of Medicine at Columbia University, College of Physicians and Surgeons.
